Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FN 1501

Next Previous
X
Search
Drug Profile

FN 1501

Alternative Names: Compound 50; FN-1501

Latest Information Update: 21 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator China Pharmaceutical University
  • Developer China Pharmaceutical University; Shanghai Fosun Pharmaceutical
  • Class Amides; Antineoplastics; Piperazines; Pyrazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Leukaemia; Solid tumours

Most Recent Events

  • 13 Jul 2022 Shanghai Fosun Pharmaceutical terminates a phase I trial in Acute myeloid leukaemia and Solid tumours (Second-line therapy or greater) in Australia and USA due to program re-prioritisation in light of the competitive landscape (IV) (NCT03690154)
  • 08 Jun 2022 Phase I development in Solid tumours and Acute myeloid leukaemia is ongoing Australia and USA (Fosun Pharma pipeline, June 2022) (NCT03690154)
  • 08 Jun 2022 Shanghai Fosun Pharmaceutical plans a clinical trial for Liver cancer (Fosun Pharma pipeline, June 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top